Bethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.
Arthur Bedrosian, president and CEO of Lannett, said: “This approval represents an important new addition to our product portfolio and is the result of the hard work and dedication of our employees. We will commence marketing our bethanechol chloride product, in the 5mg, 10mg, 25mg, and 50mg tablets, immediately.”